• FY25 revenue from continuing operations expected to be ~$139.0 million
• Four out of five core brands achieved year-on-year revenue growth
• Estimated FY25 underlying EBITDA in the order of $7.0 to $7.5 million

McPherson's Limited (ASX:MCP) has provided an update on its financial performance for the full year period ended 30 June 2025 (FY25) and its progress on the transformation of the business. Key highlights include: FY25 revenue from continuing operations expected to be in the order of $139.0 million, with four out of five core brands achieving year-on-year revenue growth in challenging trading conditions. Estimated FY25 underlying EBITDA in the order of $7.0 to $7.5 million, majority weighted to 2H25. The company has substantially completed the transition to a pharmacy and health channel wholesaler model, with the new operating model now in operation. This transition is expected to unlock incremental annual underlying EBIT benefits at the upper end of the previously provided guidance of $4.0 to $5.0 million from FY26 onwards. The company also expects material items related to operating model changes in the order of $11.0 million, comprising a mix of cash and non-cash items, as well as additional non-cash intangible asset impairments in the order of $9.0 to $11.0 million. McPherson's remains in a positive operating cash flow generation and net cash position as at 30 June 2025.

FY25 revenue from continuing operations expected to be in the order of $139.0 million. Estimated FY25 underlying EBITDA in the order of $7.0 to $7.5 million.

The new operating model, combined with earlier progress on strategic initiatives and the company's investment in its cost base, has been deliberately established to support the further growth of the business, and positions the company well to realise the benefits of future scale.